Integrated pharmacology and validation reveal Formononetin upregulates GSTM2 to modulate prostate cancer immune microenvironment via ROS/STAT3-driven chemokine reprogramming
Background Prostate cancer (PCa) is responsible for a substantial proportion of male cancer cases worldwide. Biochemical recurrence (BCR) representing a critical challenge in its disease management. Formononetin, a natural isoflavone derived from traditional Chinese medicine, has demonstrated potential anticancer prope...